MENU

ANGPTL3 Base Editing: Durable Lipid Lowering via GalNAc-LNP

Nature USA
Overview
A single-course CRISPR adenine base editing treatment targeting ANGPTL3 achieved a > 90% reduction in circulating protein in nonhuman primates, lasting up to 3 years. The therapy reduced LDL-C by 40–50% and triglycerides by 50–70% in hyperlipidemia models. These results provide the foundation for a first-in-human clinical trial for refractory hyperlipidemia syndromes.
In Depth

Key Findings

The administration of a CRISPR adenine base editor resulted in durable, liver-selective inactivation of angiopoietin-like 3 (ANGPTL3). In nonhuman primates, a single dose led to a mean reduction in circulating ANGPTL3 protein of > 90%, with effects persisting for 3 years. In both mouse and nonhuman primate models of hyperlipidemia, this gene inactivation was associated with reductions of approximately 40 to 50% in low-density lipoprotein cholesterol (LDL-C) and 50 to 70% in triglycerides.

Technical Details

The treatment utilizes a GalNAc–lipid nanoparticle (LNP) to encapsulate guide RNA and mRNA encoding the CRISPR adenine base editor. This delivery system enables liver-selective targeting. In vitro analyses using human liver cells confirmed that the base editor introduces a DNA base-pair change at the target ANGPTL3 locus. Safety assessments showed no detectable off-target editing across approximately 3000 candidate sites, nor were any treatment-related structural variants detected.

Background & Context

Circulating concentrations of LDL-C and triglyceride-rich lipoproteins are primary risk factors for atherosclerotic cardiovascular disease. While various lipid-lowering medications are approved, the chronic care treatment model often fails to help most patients achieve target lipid levels. ANGPTL3 is identified as a known driver that increases both LDL-C and triglyceride concentrations, making it a strategic target for permanent or durable inactivation.

Significance & Outlook

By shifting from chronic medication to a potential single-course treatment, this approach addresses the limitations of current lipid-management models. The durability and precision demonstrated in nonhuman primates and human liver cells have led to the initiation of an ongoing first-in-human clinical trial. This trial focuses on patients suffering from refractory hyperlipidemia syndromes.

Source: https://doi.org/10.1038/s41586-026-11233-9

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC